First-in-India manufacturing licence for Biomescan gut-health software platform

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

—Next day

—

prior close

₹90.70

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.2%—

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.4

10m

+0.2

15m

-1.2

30m

-1.2

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

—-0.1—

Next day

—-0.2—

—+0.1—

—+0.3—

—+0.4—

—+0.5—

—+0.3—

15d

—+1.9—

—+2.2—

—-1.2—

———

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lords Mark Industries has become the first and only Indian company to receive a manufacturing licence for an In Vitro Diagnostic Software (Software as a Medical Device) for its Biomescan Analytics Platform. The licence was granted under the Medical Devices Rules, 2017. Biomescan combines whole metagenome sequencing with bioinformatics to offer gut microbiome profiling, diversity scores, enterotype classification, and personalised dietary advice. The company plans to build a nationwide network of Health and Wellness Centres with hospitals and doctors to deliver preventive microbiome-based care.

Likely market impact

Positive first-mover entry into regulated gut-health diagnostics; unlocks a new preventive healthcare vertical but no revenue numbers given yet.